Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026.